过去一年中添加的文章，按日期排序
[HTML][HTML] Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 …
V Diéras, HS Han, H Wildiers, M Friedlander… - European Journal of …, 2024 - Elsevier
188 天前 - … In the intention-to-treat population (N = 509), 337 patients were randomized to
receive veliparib and 172 to placebo. Median OS was 32.4 months vs 28.2 months (hazard ratio, …
receive veliparib and 172 to placebo. Median OS was 32.4 months vs 28.2 months (hazard ratio, …
[HTML][HTML] Can we successfully define and target BRCA-like breast cancers?
N LeVasseur, KA Gelmon - Translational Cancer Research, 2024 - ncbi.nlm.nih.gov
214 天前 - … randomized double-blind, placebo-controlled phase 2 study of cisplatin 75 mg/m
2 with either veliparib 300 mg twice daily on days 1–14 or placebo … of veliparib with high-dose …
2 with either veliparib 300 mg twice daily on days 1–14 or placebo … of veliparib with high-dose …